

Curon Biopharma completes \$150M financing

01 August 2018 | News

It will use the proceeds from the financing to accelerate its pipeline assets into pre-clinical and clinical phases as well as support the company in expanding its current portfolio pipeline.



Shanghai-based biopharma firm Curon Biopharmaceutical has announced the completion of its Series A funding round, which raised \$150 million from Temasek, 6 Dimensions Capital, and Boyu Capital. Curon Biopharma is incubated by 6 Dimensions Capital, a healthcare-focused investment firm established in 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures.

According to Curon Biopharma, which is developing next-generation cancer immuno-therapies, it will use the proceeds from the financing to accelerate its pipeline assets into pre-clinical and clinical phases as well as support the company in expanding its current portfolio pipeline.

With the completion of the latest funding round, Curon also announced the appointment of Dr. Paul H. Song as its Chief Scientific Officer. Song started his career in Eli Lilly US with roles of Senior Research Scientist and Principal Research Scientist. He also joined Samsung Advanced Institute of Technology in 2010 as the vice president.